Jazz Pharmaceuticals plc (JAZZ) Form 8-K — Oct 26, 2026

$JAZZForm 8-KItems 2.02Filed Oct 26, 2026, 4:03 PM ET0001628280-26-067275Original filing

Jazz Pharmaceuticals disclosed that its Q3 2026 results will include an estimated pre-tax charge of approximately $755 million in acquired in-process research and development expense tied to its acquisition of Actio Biosciences, completed September 15, 2026. The charge is non-tax-deductible and is expected to reduce both GAAP EPS and non-GAAP adjusted EPS by roughly $11.00 for the quarter.

Key figures

Eps impact: -$11.00
Iprd pretax charge: $755 million
Acquisition close date: 2026-09-15

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.